Brief Report

Needleless connector decontamination for prevention of central venous access device infection: A pilot randomized controlled trial

Claire M Rickard PhD, Julie Flynn PhD, Emily Larsen GDHealthRes, Gabor Mihala GCBiostats, E Geoffrey Playford PhD, Joanie Shaw GCCancerNurs, Samantha Keogh PhD, Amanda Ullman PhD, Li Zhang PhD, Nicole Gavin PhD, Tricia Kleidon MN (NursePractitioner), Vineet Chopra MD, Alexandra L. McCarthy PhD, Patricia Kuerten Rocha PhD, Nicole Marsh PhD, E Geoffrey Playford PhD, Joanie Shaw GCCancerNurs, Samantha Keogh PhD, Amanda Ullman PhD, Li Zhang PhD, Nicole Gavin PhD, Tricia Kleidon MN (NursePractitioner), Vineet Chopra MD, Alexandra L. McCarthy PhD, Patricia Kuerten Rocha PhD, Nicole Marsh PhD. E Geoffrey Playford PhD, Joanie Shaw GCCancerNurs, Samantha Keogh PhD, Amanda Ullman PhD, Li Zhang PhD, Nicole Gavin PhD, Tricia Kleidon MN (NursePractitioner), Vineet Chopra MD, Alexandra L. McCarthy PhD, Patricia Kuerten Rocha PhD, Nicole Marsh PhD.

School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia

School of Nursing, Queensland University of Technology, Kelvin Grove, Queensland, Australia

School of Medicine, Griffith University, Nathan, Queensland, Australia

Infection Management Services, Princess Alexandra Hospital, Buranda, Queensland, Australia

Cancer, Immunology and Palliative Care, Gold Coast Health, Southport, Queensland, Australia

Queensland Children’s Hospital, South Brisbane, Queensland, Australia

School of Dental Health Science, Griffith University, Gold Coast, Queensland, Australia

Internal Medicine, University of Michigan, Ann Arbor, MI

School of Nursing, University of Queensland, St Lucia, Queensland, Australia

Federal University of Santa Catarina, Florianopolis, SC, Brazil

E-mail address: c.rickard@griffith.edu.au (C.M. Rickard).

Conflicts of Interest: C.M.R.[220s employer, Griffith University, has received unrestricted investigator-initiated research grants on her behalf from [BD-Bard; Cardinal Health], and consultancy payments on her behalf from manufacturers (3M, BBraun, BD-Bard); E.L.[220s employer, Griffith University, has received on her behalf, an investigator-initiated grant from Cardinal Health (formerly Medtronic); E.L. has received an educational (conference) scholarship from Angiodynamics. S.K.[220s current employer (QUT) has received unrestricted educational grants on her behalf from product manufacturers (BD Medical). Griffith University (affiliated institution) has received consultancy payments on her behalf from manufacturers (BD Medical). A.J.U.[220s employer Griffith University has received unrestricted research grants and payments for educational lectures from 3M, Becton Dickinson [BD]-Bard, BBraun, and Cardinal Health on her behalf (unrelated to current project). T.M.K.[220s employer, Griffith University, has received funding on her behalf for investigator-initiated research or educational grants from BD-Bard and Cardinal health; in addition to funding on her behalf for consultancy lectures or advice from 3M, Access Scientific, BD-Bard, Medical Specialities Australia and VYGON. V.C. has received grant support from the Agency for Healthcare Research and Quality and the American Hospital Association. He has also received royalties from Wolters Kluwer Health and Oxford University Press related to books he has authored. N.M.[220s previous employer Griffith University has received on her behalf investigator-initiated research grants from Becton Dickinson, and Cardinal Health and a consultancy payment provided to Griffith University from Becton Dickinson for clinical feedback all things (unrelated to the current project). No other conflicts to report.

BACKGROUND

Central venous access devices (CVADs) risk central line-associated bloodstream infection (CLABSI) which increase costs, morbidity and mortality. The intraluminal infection source can be minimized by needleless connector (NC) decontamination prior to each use using chlorhexidine gluconate (CHG), povidone-iodine, or 70% isopropyl alcohol (IPA). The optimal antiseptic is unknown, although povidone-iodine’s slow dry-time presents challenges in clinical practice. Combination CHG/IPA wipes, or IPA in a cap format may be superior to traditional intermittent 70% IPA wipes, but no randomized controlled trials (RCTs) have been completed. Our aim was to perform a pilot randomized controlled trial (180 patients) of needleless connector decontamination. Central line-associated bloodstream infection occurred in 2% (1/61) of 70% isopropyl alcohol (IPA) wipe, 2% (1/59) of 70% IPA cap, and zero (0/58) infections in 2% chlorhexidine gluconate in 70% IPA wipe patients. Larger definitive trials are feasible and needed.

© 2020 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.

(http://creativecommons.org/licenses/by-nc-nd/4.0/)
generate feasibility and pilot data comparing 70% IPA wipes, 2% CHG in 70% IPA wipes, and 70% IPA caps.

**MATERIALS AND METHODS**

**Setting and study design**

Three-arm pilot RCT at the Royal Brisbane and Women’s Hospital and Gold Coast University Hospital in Australia. We had University and Hospital Ethics Committees approval (2016/410; HREC/15/QRWB/553) and Australian New Zealand Clinical Trials Registry registration: 12615001120561. The 4-week intervention had follow-up until 48 hours post study completion, hospital discharge or device removal. We surveyed registered nurses (RNs) for protocol compliance and satisfaction.

**Participants and sample size**

Eligibility criteria: ≥18 years of age; CVAD (peripherally inserted central catheter or tunneled, cuffed CVAD) inserted <24 hours; CVAD required for ≥7 days; and written consent. Exclusions: baseline bloodstream infection, non-English speaking without interpreter, or previous enrollment. Research nurses (ReNs) screened daily, gave trial information, and obtained consent. The target was 60 per group (1 CVAD per patient) with recruitment July 31, 2017 to April 5, 2019.7

**Randomization and blinding**

Centralized, computer-generated randomization (https://randomisation.griffith.edu.au) using randomly varying permuted blocks of 3 and 6 (1:1:1 ratio); (1) 70% IPA wipes, (2) 2% CHG in 70% IPA wipes, or (3) 70% IPA caps. Clinical outcome assessors and data analysts were masked.

**Interventions**

- Seventy percent IPA wipes: 0.6 mL Alcohol Prep Pads (Reynard, New Zealand) applied vigorously to NC for 5 seconds (manufacturer-recommended and hospital policy), visibly dry prior to CVAD access;
- Two percent CHG in 70% IPA wipes: 0.6 mL Alcohol and CHG Prep Pads (Reynard, New Zealand), applied vigorously to NC for 15 seconds (guideline recommendation8), visibly dry prior to CVAD access;
- Seventy percent IPA cap: Luer access valve cap Swabcap (intensive care unit [ICU] Medical, San Clemente) screwed onto NCs for minimum 5 minutes (manufacturer-recommended) prior to each access (70% IPA wipes were also used), then replaced with a new cap.

NCs were Smartsite Needle-Free Valve or Max Plus (both Carefu

**Primary outcome(s)**

Protocol feasibility was assessed as: (1) eligibility, (2) retention and attrition, (3) protocol adherence, (4) missing data, and (5) RN satisfaction.

**Secondary outcome(s)**

- (i) CLABSI9 (2018 National Health and Safety Network definition) assessed by masked infectious diseases specialist;
- (ii) Mortality (all-cause) during trial;
- (iii) Primary bloodstream infection (laboratory confirmed bloodstream infection)9;
- (iv) CVAD (tip) colonization (≥15 colony-forming units, semi-quantitative culture).1

**Adverse events**

We captured all potentially intervention-related events, and all-cause ICU admission (serious adverse event).

**Statistical analysis**

Research Electronic Data Capture (REDCap, Nashville, TN) and Stata 15 (College Station, TX) were used. Feasibility outcomes were analyzed against predetermined criteria (≥80% of screened patients eligible and ≥80% eligible patients recruited; ≥95% retention and attrition (not withdrawn/lost to follow-up); >90% study visits with correct products in use, and self-reported RN adherence to application/dry times; 5% missing data (CLABSI endpoint); RN satisfaction on 1-10 numerical rating scale.

Clinical outcomes were compared using Fisher’s exact and log-rank tests, incidence rates and Kaplan-Meier survival estimates (P < .05 statistically significant; patients censored at discharge). A modified intention-to-treat analysis excluded only randomized patients who never received a CVAD.

**RESULTS**

Patient/device characteristics are presented in Table 1 and Supplementary Table 1. Average CVAD dwell-times were 11.3, 9.3, and 7.4 days in the 70% IPA, 2% CHG in 70% IPA, and 70% IPA cap groups, respectively.

**Primary outcomes**

Seventy percent (211/303) of screened patients were eligible and 85% (180/211) were randomized (31 declined, missed, or had CHG allergy: Fig 1). Two patients were excluded postrandomization due to CVAD insertion failure. There was 100% retention, 0% attrition, and 0% missing CLABSI endpoints (Fig 1). Thus, 178 patients were analyzed.

Observed protocol adherence was 98% (174/178); all but three 2% CHG in 70% IPA wipe and two 70% IPA cap patients commenced the correct intervention. 70% IPA wipe patients had no protocol deviations. At least one incorrect product use occurred in 5% (3/58) 2% CHG in 70% IPA, and 10% (6/59) 70% IPA cap patients.

Of 35 RNs (40 surveyed, response rate 88%), protocol-adherent scrub times were reported by 31 (89%) for 70% IPA wipe, and 26 (74%) for 2% CHG in 70% IPA wipe. Median satisfaction was 9 (interquartile range: 2), 10 (2), and 9 (2) for 70% IPA wipes, 2% CHG in 70% IPA wipes, and 70% IPA caps, respectively (N = 22 for 70% IPA caps; not all RNs had used these).

**Secondary outcomes**

CLABSI occurred in 1/61 (2%) 70% IPA wipe, 0/58 (0%) 2% CHG in 70% IPA wipe, and 1/59 (2%) 70% IPA cap patients (P = 1.0, Fig 2). CLABSI incidence per 1,000 catheter-days was 1.38 (95% confidence interval [CI]: 0.19-9.81), nil (no outcomes), and 1.70 (95% CI:
0.24–12.1) for 70% IPA wipes, 2% CHG in 70% IPA wipes, and 70% IPA caps, respectively ($P = .637$).

Primary bloodstream infections occurred in 2/61 (3%) 70% IPA wipe, 2/58 (3%) CHG in 70% IPA wipe (1 of these was a mucosal barrier infection), and 1/59 (2%) 70% IPA cap patients. There were no deaths and no positive catheter tips (N = 10 cultured).

Adverse events

Two 70% IPA cap NCs became opaque (IPA appeared to seep between the rubber inner and outer plastic, denaturing the plastic but with no effect on patients). Four patients required transfer to ICU for unrelated reasons (n = 3, 70% IPA wipe; n = 1, 70% IPA cap).

DISCUSSION

NC decontamination is a high-volume, high-value practice that urgently needs high-quality evidence to prevent CLABSI. This pilot RCT confirms the feasibility of large RCTs, with acceptable recruitment, protocol adherence, and RN satisfaction, as well as high retention, low attrition and no missing data. Eligibility at 70% could be improved with amplified research nurse availability at device insertion to promote recruitment.

CLABSI incidence was low in both groups using 70% IPA, and 0 when this antiseptic was combined with CHG. These results are consistent with laboratory data, and a large RCT on pre-CVAD insertion skin decontamination which both favored combination CHG and IPA; a larger RCT would be needed to substantiate these findings in NCs. Although scrub times differed (15 seconds for 2% CHG in 70% IPA wipe as per guidelines, and 5 seconds for 70% IPA wipes as per manufacturers and hospital policy), recent data indicates no difference in effectiveness with 5, 10, or 15 second scrub times.

CLABSI was infrequent, however as >50% were patients were discharged during follow-up, future RCTs should study the entire CVAD dwell (including home care) to ensure adequate sample size to test hypotheses and generalizability. Nevertheless, our CLABSI of approximately 1 per 1,000 catheter-days, is similar to reported USA rates, but may not be generalizable where rates are higher. Despite low frequency, CLABSI remains the most appropriate outcome to assess NC disinfection efficacy. Other methods such as routine CVAD tip culture have poor positive predictive value.

Insertion bundles have reduced CLABSI, with focus now needed on techniques to prevent postinsertion, intraluminal bacterial entry. Currently, 70% IPA wipes are dominant due to low cost, availability and rapid drying; however the addition of CHG likely increases efficacy, and nonrandomized studies support 70% IPA caps. Pilot RCTs are not designed to test statistical differences in outcomes or for the effect of potential confounders or covariates such as NC/device type or patient factors. Large RCTs are needed to examine various modes and strengths of antiseptics, NC materials/designs, and

| Table 1 |
|:--------|:--------|:--------|:--------|:--------|
| Participant (N = 180) and device (N = 178) characteristics at baseline |
| | 70% IPA | 2% CHG in 70% IPA | 70% IPA cap | Total |
| Participants per study groups* | 61 (34) | 59 (33) | 60 (33) | 180 (100) |
| Age (years) | 61 (50–67) | 60 (47–67) | 63 (50–72) | 61 (50–70) |
| Sex: male | 31 (51) | 28 (47) | 37 (62) | 96 (53) |
| Cancer treatment | 19 (31) | 18 (31) | 17 (28) | 54 (30) |
| Admission type | - surgical | 47 (77) | 46 (78) | 49 (82) | 142 (79) |
| | - haematology | 12 (20) | 10 (17) | 10 (17) | 32 (18) |
| | - medical | 1 (2) | 3 (5) | 1 (2) | 5 (3) |
| | - medical oncology | 1 (2) | 0 (0) | 0 (0) | 1 (1) |
| Comorbidities | - nil or one | 17 (28) | 17 (29) | 16 (27) | 50 (28) |
| | - two or three | 20 (33) | 16 (27) | 20 (33) | 56 (31) |
| | - four or more | 24 (39) | 26 (44) | 24 (40) | 74 (41) |
| Leucocytes $<500/\mu l$ (n=179) | 5 (8) | 5 (9) | 5 (8) | 15 (8) |
| Pre-existing infection | 27 (44) | 32 (54) | 34 (57) | 93 (52) |
| Devices by study groups* | 61 (34) | 58 (33) | 59 (33) | 178 (100) |
| Device type | - PICC | 57 (93) | 54 (93) | 56 (95) | 167 (94) |
| | - TC | 4 (7) | 4 (7) | 3 (5) | 11 (6) |
| No. of lumens | - one | 16 (26) | 21 (36) | 20 (34) | 57 (32) |
| | - two | 45 (74) | 37 (64) | 39 (66) | 121 (68) |
| Location | - upper arm | 57 (93) | 54 (93) | 56 (95) | 167 (94) |
| | - chest | 4 (7) | 4 (7) | 3 (5) | 11 (6) |
| IV medications | - antibiotics | 43 (70) | 39 (67) | 42 (71) | 124 (75) |
| | - fluids | 24 (39) | 25 (43) | 21 (36) | 70 (39) |
| | - blood product | 9 (15) | 13 (22) | 5 (8) | 27 (15) |
| | - antiseptic | 9 (15) | 7 (12) | 9 (15) | 25 (14) |
| | - parenteral nutrition | 12 (20) | 6 (10) | 6 (10) | 24 (13) |
| | - potassium chloride | 6 (10) | 6 (10) | 4 (7) | 16 (9) |
| | - chemotherapy | 4 (7) | 5 (9) | 5 (8) | 14 (8) |
| | - antifungal/antiviral | 4 (7) | 1 (2) | 2 (3) | 7 (4) |
| | - other medication | 29 (48) | 25 (43) | 17 (29) | 71 (40) |
| No medications (fluids only) | 5 (8) | 6 (10) | 7 (12) | 18 (10) |

Frequencies and column percentages shown unless otherwise noted.
*Row percentage shown.
$y$ Median and interquartile range (25th and 75th percentiles) shown.
$z$ In previous 6 months.
$x$ Absolute, within 72 hours of trial entry.
Fig 1. CONSORT flowchart. CHG, chlorhexidine gluconate; CVAD, central venous access device; IPA, isopropyl alcohol; mITT, modified intention-to-treat.

Fig 2. Kaplan-Meier survival estimates for central line-associated bloodstream infection by study group. CHG, chlorhexidine gluconate; IPA, isopropyl alcohol.
monitor possible new adverse events as solutions are exposed to NCs and potentially the bloodstream.

Acknowledgments

We thank Marie Cooke, Peter Mollee, Paul Scuffham, and Joan Webster for assistance in obtaining funding and Aidan Menzies for formatting assistance. We thank Christine Woods, Alyson Eastgate, Elise Sturgeon and Melissa Williams for assistance with patient recruitment and data collection. We thank the patients, relatives and staff of the participating hospitals.

SUPPLEMENTARY MATERIALS

Supplementary material associated with this article can be found in the online version at https://doi.org/10.1016/j.ajic.2020.07.026.

References